A high-protein diet combined with aflatoxin exposure has been associated with increased preneoplastic hepatic lesions in rats.48 However, while low-protein diets decrease hepatocarcinogenicity, they appear to predispose patients to a subacute toxicosis.49 Thus, recovering dogs should be fed a balanced canine diet. Avoid protein -restricted diets unless hepatoencephalopathy
is suspected. In cases of hepatoencephalopathy, parenteral nutrition may be preferred.43
Frequently monitor the clinical signs; hepatic enzyme activities; electrolyte, cholesterol, and bilirubin concentrations;
coagulation parameters; and hepatic function of patients with aflatoxicosis. Pay particular attention to any signs of DIC,
hepatoencephalopathy, or severe bleeding. Recovering dogs should undergo periodic serum chemistry profiles and liver function
testing (e.g. bile acid assay). Also screen dogs with a history of aflatoxin ingestion but no clinical signs for biochemical or hematologic
abnormalities because clinical signs of aflatoxicosis are not always immediately apparent, and early treatment may decrease
morbidity and mortality.13,16,18
LONG-TERM PATIENT OUTCOME
Dogs with aflatoxicosis can develop chronic liver disease and may be prone to developing neoplastic hepatic disorders. Hepatocarcinogenicity
has been documented as a sequela to aflatoxin exposure in people, but no information is available regarding carcinogenicity
Canine aflatoxicosis occurs from ingestion of aflatoxin-contaminated foods. Aflatoxins cause severe hepatic damage that frequently
results in liver failure. The mainstays of treatment are hepatoprotective nutraceuticals, fluid therapy, blood component therapy,
vitamin K1, antiemetics, and gastrointestinal protectants. While aflatoxicosis is fatal in most patients with overt signs of intoxication,
some dogs may recover slowly with long-term care.
The author wishes to thank Lisa Murphy, VMD, DABT, and Meredith Daly, VMD, for their contributions to this article.
"Toxicology Brief" was contributed by Eva Furrow, VMD, Department of Clinical Studies, School of Veterinary Medicine, University
of Pennsylvania, Philadelphia, PA 19104-4912. The department editor is Petra Volmer, DVM, MS, DABVT, DABT.
1. Seibold HR, Bailey WS. An epizootic of hepatitis in the dog. J Am Vet Med Assoc 1952;121:201-206.
2. Seibold HR. Hepatitis X in dogs. Vet Med 1953;48:242-243.
3. Newberne JW, Bailey WS, Seibold HR. Notes on a recent outbreak and experimental reproduction of hepatitis X in dogs. J Am Vet Med Assoc 1955;127:59-62.
4. Chaffee VW, Edds GT, Himes JA, et al. Aflatoxicosis in dogs. Am J Vet Res 1969;30:1737-1749.
5. Bailey WS, Groth AH. The relationship of hepatitis X of dogs and moldy corn poisoning of swine. J Am Vet Med Assoc 1959;134:514-516.
6. Newberne PM, Russo R, Wogan GN. Acute toxicity of aflatoxin B1 in the dog. Pathol Vet 1966;3:331-340.
7. Edds GT. Acute aflatoxicosis: a review. J Am Vet Med Assoc 1973;162:304-309.
8. Newberne PM. Chronic aflatoxicosis. J Am Vet Med Assoc 1973;163:1262-1267.
9. Williams JH, Phillips TD, Jolly PE, et al. Human aflatoxicosis in developing countries: a review of toxicology, exposure,
potential health consequences, and interventions. Am J Clin Nutr 2004;80:1106-1122.
10. Kuilman ME, Maas RF, Fink-Gremmels JF. Cytochrome P450-mediated metabolism and cytotoxicity of aflatoxin B(1) in bovine hepatocytes.
Toxicol In Vitro 2000;14:321-327.
11. Wang JS, Groopman JD. DNA damage by mycotoxins. Mutat Res 1999;424:167-181.